All News
Very cool preclinical plenary @MaxKonigMD
Instead of CAR-T to just CD19, created CATCRs that selectively kill specific B cells (beta2 glycoprotein expressing cells)
Early days but super interesting possibilities - APS, SLE, AAV, & more?
#ACR22 @rheumnow #ACRBest Abstr#1677 https://t.co/nS3YtR6wN9
Mike Putman EBRheum ( View Tweet)
#ACR22 highlights. #PMR May have Steroid sparing options. #tocilizumab abst#1106, #tofacitinib abst1107, #sarilumab #1676. Also previous #secukinumab ALL positive RCTs #ACRBest @RheumNow
Janet Pope Janetbirdope ( View Tweet)
Izmirly et al. HCQ crosses placenta but no evidence ocular toxicity in children at 5 years old by OCT @RheumNow #ACR22 Abstr#1674 https://t.co/yMQzt6sU7i
Richard Conway RichardPAConway ( View Tweet)
Chimeric autoantigen-T cell receptor (CATCR)-T cell therapies:
precision cellular therapy
selectively deplete autoreactive B cells
@MaxKonigMD in the plenary:
CATCR can take out anti-b2GPI autoAbs crucial to antiphospholipid syndrome, but preserve normal B cells
#ACR22 @RheumNow https://t.co/5ZLocrwqKY
David Liew drdavidliew ( View Tweet)
GWAS analysis of 2.5m people (120k with gout) showing identifies 1486 candidate causal genes for gout. Looking at urate handling as well as disease propagation (eg. IL1/6). Widespread GWAS allowing us to investigate these diseases differently.
@RheumNow #ACR22 #Plenary
Julian Segan JulianSegan ( View Tweet)
#ACR22 Highlights. ILD in CTDs #rituximab = #cyclophoshamide at 6 mo for CTD ILD & ritux better on skin score in #scleroderma RECITAL RCT abst0003 but #pirfenidone added to #MMF not better than MMF alone in SLSIII RCT—ILD w #SSc abst#520 vs in SENCIS #nintedanib is + @RheumNow
Janet Pope Janetbirdope ( View Tweet)
Great moderating PMR talk w/@SattuiSEMD this AM; phenomenal slides @drceowen re:imaging in PMR
Big ?s:
-Who needs this? All/some/many
-Which modality? Nice summary slide
-How to treat "subclinical" GCA (risk of overtreatment imo)
Ideas for next year?
#ACR22 @rheumnow #ACRBest https://t.co/akvsud3YVO
Mike Putman EBRheum ( View Tweet)
Preterm delivery and HTN disorders in #vasculitis
Abstract #0953 #ACR22 @RheumNow @StanfordRheum
🤰87 deliveries from 1991-2012
🤰Higher risk for preterm delivery (PTD) (RR 4), PPROM (RR 4), HTN dx of preg. (RR 3)
🤰Of spon. PTD, 17% born between 20-31 weeks
Catherine Sims, MD DrCassySims ( View Tweet)
Can Neural Networks Answer Important Diagnostic Dilemmas in Rheumatology? #ACR22
https://t.co/TThsEQ7RDH https://t.co/ZHNlH3J0de
Links:
Dr. John Cush RheumNow ( View Tweet)
Ab1676 #ACR22 SAPHYR: Sarilumab in Refractory PMR
52wk SAR 200 mg q2w + 14w taper GC v PBO+GC taper
Primary endpt: sustain response at 52w
Early term 2/2 COVID, 117 pt
SAR remission 28% vs PBO 10%, p=0.02
Data consistent when removes CRP data
PBO: more GCs 2/2 PMR flare
@Rheumnow https://t.co/kHq3juULX1
Eric Dein ericdeinmd ( View Tweet)
How much does diet and exercise help in knee osteoarthritis?
Pragmatic RCT (WE-CAN), n=823
a diet & exercise intervention program led to:
- 10kg weight loss
- some significant pain improvements
We need to fund diet & exercise programs for OA patients!
ABST1675 #ACR22 @RheumNow https://t.co/Ctm8ZoRF3o
David Liew drdavidliew ( View Tweet)
Update on ACR Guideline on Prevention and Treatment of GIOP.
Sequential Rx when initial OP Rx and GC discontinued
https://t.co/TWdI728pCp
Mary Beth Humphrey #ACR22 @RheumNow https://t.co/i320si4RJp
Links:
Dr. Antoni Chan synovialjoints ( View Tweet)
Sarilumab (IL-6R inhibitor) in phase 3 trial for relapsing PMR (SAPHYR trial).
Key inclusion: Disease flare while taking >7.5mg prednisolone
Sustained remission: resolution of symptoms, normalisation of CRP, adherence to prednisolone taper
@RheumNow #ACR22 #Plenary
Julian Segan JulianSegan ( View Tweet)
Spiera et al. Sarilumab in refractory PMR (SAPHYR) - Phase 3 RCT. Significant effect of IL-6i. @RheumNow #ACR22 Abstr#1676 https://t.co/2MS441B8gU https://t.co/jBd7YJKrTs
Richard Conway RichardPAConway ( View Tweet)
#ACR highlights - #pegloticase in #gout - less reactions and more benefit w #MTX MIRROR RCT. Better than no MTX. Will change my practice - if I can access to a #peguricase, I will Rx w concomitant MTX Abst#0001 #ACR22 @RheumNow
Janet Pope Janetbirdope ( View Tweet)
Updated ACR Guidelines on Prevention and Rx of GIOP
Rx recommendations when new fractures occur after 12 months of initial OP Rx
https://t.co/TWdI728pCp
Mary Beth Humphrey #ACR22 @RheumNow https://t.co/wHANvymd5R
Links:
Dr. Antoni Chan synovialjoints ( View Tweet)
Updated ACR Guidelines on Prevention and Rx of GIOP
OP Rx in special populations
https://t.co/TWdI728XrX
Mary Beth Humphrey #ACR22 @RheumNow https://t.co/0h72a4jXmG
Links:
Dr. Antoni Chan synovialjoints ( View Tweet)
PATCH study, 👁 safety data in children 5 yrs after birth
In utero HCQ exposure does NOT:
-impact retinal morphology (OCT)
-reduce significantly retinal thickness
https://t.co/D7SgPG6PX4
Abs#1647 #ACR22 @RheumNow
Aurelie Najm AurelieRheumo ( View Tweet)
WE-CAN pragmatic RCT on community-dwelling ♂️&♀️ >/=50y w/ knee #osteoarthritis & obesity:
💠Diet + exercise = significant weight ⬇️and ☑️WOMAC pain score, WOMAC function, 6min walk distance & SF-36 HRQoL
🍽️+🚶♀️in OA? = Yes we can!
#ACR22 @RheumNow @rheumarhyme https://t.co/Ty2boH52HC
sheila RHEUMarampa ( View Tweet)
Ab1675 #ACR22 WE-CAN - Knee OA
823 randomized pts, 18 mo: Intensive Diet & Exercise (D+E)
Primary endpt: WOMAC pain - 32% reduct in pain in D+E, vs 24% (PBO)
20% more likely: clinically meaningful improve
Improved BMI, 6MW, HRQoL, activity
Pain Rx, depression: no change
@RheumNow https://t.co/Su2g4Z38FV
Eric Dein ericdeinmd ( View Tweet)